Robust improvements in fasting and prandial measures of β‐cell function with vildagliptin in drug‐naïve patients: analysis of pooled vildagliptin monotherapy database
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Aim: To assess the effects of 24‐week treatment with vildagliptin on measures of β‐cell function in a broad spectrum of drug‐naïve patients with type 2 diabetes (T2DM). Methods: Data from all double‐blind, multicentre, randomized, placebo‐ or active‐controlled trials conducted in drug‐naïve patients with T2DM were pooled from all patients receiving monotherapy with vildagliptin (100 mg daily: 50 mg twice daily or 100 mg once daily, n = 1855) or placebo (n = 347). Fasting measures of β‐cell function [homeostasis model assessment of β‐cell function (HOMA‐B) and proinsulin : insulin ratio] were assessed in the overall pooled monotherapy population. Standard meal tests were performed at baseline and week 24 in a subset of patients, and effects of vildagliptin (100 mg daily, n = 227) on dynamic (meal test–derived) measures of β‐cell function [insulin secretion rate relative to glucose (ISR/G) and insulinogenic indices] were assessed relative to baseline and vs. placebo (n = 29). Results: In the overall population, vildagliptin significantly increased HOMA‐B both relative to baseline [adjusted mean change (AMΔ) = 10.3 ± 1.5] and vs. placebo (between‐treatment difference in AMΔ = 11.5 ± 4.5, p = 0.01) and significantly decreased the proinsulin : insulin ratio relative to baseline (AMΔ = −0.05 ± 0.01) and vs. placebo (between‐treatment difference in AMΔ = −0.09 ± 0.02, p < 0.001). Relative to baseline, vildagliptin monotherapy significantly increased all meal test–derived parameters, and ISR/G (between‐treatment difference in AMΔ = 9.8 ± 2.8 pmol/min/m 2 /mM, p < 0.001) and the insulinogenic index 0–peak glucose (between‐treatment difference in AMΔ = 0.24 ± 0.05 pmol/mmol, p = 0.045) were significantly increased vs. placebo. Conclusions: Vildagliptin monotherapy consistently produced robust improvements in both fasting and meal test–derived measures of β‐cell function across a broad spectrum of drug‐naïve patients with T2DM. All Phase III trials described (NCT 00099905, NCT 00099866, NCT 00099918, NCT 00101673, NCT 00101803 and NCT 00120536) are registered with ClinicalTrials.gov.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255
Self-citationCharacterization of GLP-1 Effects on β-Cell Function After Meal Ingestion in Humans
Ahrén, B., Holst, J. J., & Mari, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2860 · Cited by 72
Cited by
Del Prato, S., Barnett, A. H., Huisman, H., Neubacher, D., Woerle, H. ‐., & Dugi, K. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01350.x · Cited by 299
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
Rosenstock, J., Aguilar-Salinas, C., Klein, E., Nepal, S., List, J., Chen, R., & for the CV181-011 Study Investigators (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903178735 · Cited by 288
Self-citationAssessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1135 · Cited by 99
Self-citation
Metadata
- Authors
- Pratley, R. E., Schweizer, A., Rosenstock, J., Foley, J. E., Banerji, M. A., Pi‐Sunyer, F. X., Mills, D., & Dejager, S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2008-09-15
- Volume
- 10
- Issue
- 10
- Pages
- 931-938
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2089095955
- Cited by
- 65
- References
- 2
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Robust improvements in fasting and prandial measures of β‐cell function with vildagliptin in drug‐naïve patients: analysis of pooled vildagliptin monotherapy database. https://app.cochat.ai/papers/10.1111/j.1463-1326.2007.00835.x
- The paper
- Pratley, R. E., Schweizer, A., Rosenstock, J., Foley, J. E., Banerji, M. A., Pi‐Sunyer, F. X., Mills, D., & Dejager, S. (2008). Robust improvements in fasting and prandial measures of β‐cell function with vildagliptin in drug‐naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2007.00835.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.